🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Advocating for pts is arguably the most important thing we do in cancer research. Listen to newest NRG Oncology podcast on what advocacy is all about w/ Tambre Leighn, MA, CPC she/her . open.spotify.com/episode/4E5CGQ… Lauren Henke, MD, MSCI Stephen Chun National Cancer Institute RTOG Foundation NSABP Foundation

We asked the study team to explain NRG-CC014, the PREEMPT Study, which recently activated & is now enrolling patients with high-risk bone asymptomatic metastases. ow.ly/TngB50VSJnK Sign up for the webinar to learn more about this trial. ⬇️ Erin Gillespie, MD MPH

The NSABP Foundation Operations Center and Pathology Lab will be closed on Monday, May 26, 2025, in observance of Memorial Day.

Attending #ASCO25 this week? Check out our listing of NRG Oncology research being presented at the meeting: ow.ly/AyuN50VY12m

Listen for special episode of NRG Oncology Podcast with Vicente Valero and Julie Gralow on LBA results of BR003 for triple neg breast cancer live at ASCO 6/1/25. nrgoncology.org/Podcast Lauren Henke, MD, MSCI MD Anderson Cancer Center National Cancer Institute RTOG Foundation NSABP Foundation

Is there role for carboplatin in high-risk triple negative #breast cancer? Listen to NRG Oncology Podcast from ASCO 2025 on late breaking results of BR003 w Vicente Valero and Julie Gralow. Lauren Henke, MD, MSCI MD Anderson Cancer Center RTOG Foundation NSABP Foundation

With #ASCO25 in just a few days, we look forward to discussing high-risk triple negative #breastcancer following the late-breaking results of NRG-BR003 on Sunday! Find out where to follow: nrgoncology.org/podcast Julie Gralow ASCO MD Anderson Cancer Center Stephen Chun Lauren Henke, MD, MSCI

Special episode of NRG Oncology on LBA results of BR003 for triple negative breast cancer - Stephen Chun Julie Gralow oncodaily.com/blog/stephen-c… #OncoDaily #Oncology #Cancer #Health #Medicine #ASCO25

The NSABP B-41 study will be the subject of 2 poster presentations at #ASCO2025 on Monday. NSABP B-41: AC Followed by a Combination of Paclitaxel +Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive #breastcancer ⤵️

The NSABP B-41 study will be the subject of 2 poster presentations at #ASCO2025 on Monday. NSABP B-41: AC Followed by a Combination of Paclitaxel +Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive hashtag#breastcancer⬇️

NRG Oncology (& our foundations, The GOG Foundation Inc., NSABP Foundation, RTOG Foundation) research being presented at the hashtag#ASCO25 meeting: ow.ly/AyuN50VY12m

Here's what's on tap for today at #ASCO25 for NRG Oncology. ⬇️ Oh hey, we have a podcast episode about NRG-BR003 with Dr. Valero & Gralow coming out too! Find out where to follow: nrgoncology.org/podcast Julie Gralow ASCO MD Anderson Cancer Center Stephen Chun Lauren Henke, MD, MSCI

Let's discuss the NRG-BR003 results just presented at #ASCO25 and dive a bit deeper into the world of triple-negative breast cancer: nrgoncology.org/podcast (on Spotify, Apple, Amazon & YouTube) Julie Gralow MD Anderson Cancer Center ASCO Stephen Chun Lauren Henke, MD, MSCI

This morning at #ASCO25, Dr. Valero presented the late-breaking results of NRG-BR003. This trial enrolled patients with operable node-positive or high-risk node-negative triple-negative #breastcancer who had undergone either a mastectomy or lumpectomy. 📸Dr. Shannon Puhalla

Check out The NRG-BR003 Results in Triple-Negative Breast Cancer from The NRG Oncology Podcast on Amazon Music. music.amazon.com/podcasts/899d5…

Congratulations to MD Anderson Cancer Center Vicente Valero presenting results of NRG Oncology BR003 at #ASCO2025 . open.spotify.com/episode/4NcMsW… ASCO Julie Gralow Lauren Henke, MD, MSCI Naoto T Ueno, MD, PhD RTOG Foundation NSABP Foundation National Cancer Institute Conquer Cancer, the ASCO Foundation

No role for carbo with paclitaxel in triple negative breast cancer NRG Oncology BR 003 study !

PRESS RELEASE! NRG-NSABP B-51/RTOG 1304 shows the addition of regional nodal irradiation does not decrease rates of invasive #BreastCancer recurrence in patients whose axillary nodes convert from positive to negative following neoadjuvant chemotherapy. ➡️ow.ly/XmgR50W4Tnf

The findings of NRG-NSABP B-51/RTOG 1304 were published in NEJM this morning! Make sure to tune in.